Rabeprazole is a proton pump inhibitor (PPI) presenting a very advantageous pharmacodynamic and pharmacokinetic profile over older PPIs. In particular, this drug has a very fast onset of action, due to a short activation time and a very high pKa, and may therefore be defined as a 'second generation' PPI. The aim of this article is to provide an update on the pharmacology and clinical profile of rabeprazole and its use in acid-related disorders, with a particular focus on its role in gastroesophageal reflux disease; in the treatment and prevention of duodenal and gastric ulcers and Zollinger-Ellison syndrome; in the therapy of the extraesophageal manifestations of gastroesophageal reflux disease (in particular the respiratory and ear, nose and throat ones); and in the eradication of Helicobacter pylori.
|Titolo:||Rabeprazole : a second-generation proton pump inhibitor in the treatment of acid-related disease|
|Parole Chiave:||Acid-related disorder; Atypical symptoms; Gastroesophageal reflux disease; Helicobacter pylori eradication; Peptic ulcer disease; Proton pump; Rabeprazole; Zollinger-Ellison syndrome|
|Settore Scientifico Disciplinare:||Settore MED/12 - Gastroenterologia|
|Data di pubblicazione:||2008|
|Digital Object Identifier (DOI):||10.1586/17474184.108.40.2069|
|Appare nelle tipologie:||01 - Articolo su periodico|